Core Laboratories Inc. $CLB Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. reduced its stake in Core Laboratories by 3.1%, selling 174,600 shares and now owns approximately 11.55% of the company, valued at $81.2 million.
• Several institutional investors have recently modified their positions in Core Laboratories, with GAMMA Investing LLC increasing its stake by 972.6% and Millennium Management LLC growing its holdings by 429.0%.
• Core Laboratories announced a quarterly dividend of $0.01 per share, reflecting an annualized dividend yield of 0.4%, with record stockholders set to receive payment on August 25th.

Vanguard Group Inc. cut its holdings in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 3.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,416,618 shares of the oil and gas company's stock after selling 174,600 shares during the quarter. Vanguard Group Inc. owned 11.55% of Core Laboratories worth $81,195,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Assetmark Inc. increased its stake in shares of Core Laboratories by 92.5% in the first quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock worth $43,000 after buying an additional 1,387 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Core Laboratories by 843.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock worth $57,000 after buying an additional 2,936 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Core Laboratories in the fourth quarter worth $123,000. XTX Topco Ltd purchased a new position in Core Laboratories during the 1st quarter valued at $155,000. Finally, Sherbrooke Park Advisers LLC purchased a new position in Core Laboratories during the 4th quarter valued at $176,000. 97.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on CLB shares. Wall Street Zen upgraded shares of Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Zacks Research raised shares of Core Laboratories from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Citigroup dropped their price target on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Finally, Stifel Nicolaus lowered their target price on Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $12.50.

Core Laboratories Stock Up 0.0%

NYSE CLB traded up $0.00 during trading on Thursday, hitting $11.14. The company's stock had a trading volume of 138,790 shares, compared to its average volume of 455,157. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.27 and a quick ratio of 1.70. The company has a market cap of $522.45 million, a PE ratio of 17.97, a P/E/G ratio of 3.36 and a beta of 1.41. The business's 50 day simple moving average is $11.49 and its 200-day simple moving average is $12.67. Core Laboratories Inc. has a fifty-two week low of $9.72 and a fifty-two week high of $21.83.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. The business had revenue of $130.16 million during the quarter, compared to the consensus estimate of $129.19 million. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.The company's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the company earned $0.22 earnings per share. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. On average, equities analysts anticipate that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 25th. Shareholders of record on Monday, August 4th were issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Monday, August 4th. Core Laboratories's dividend payout ratio (DPR) is currently 6.45%.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.